A glycoprotein, termed amphiregulin (AR), inhibits growth of several human carcinoma cells in culture and stimulates proliferation of human fibroblasts and certain other tumor cells. It has been purified to apparent homogeneity from serum-free conditioned medium of MCF-7 human breast carcinoma cells that had been treated with phorbol 12-myristate 13-acetate. AR is, a single-chain extremely hydrophilic glycoprotein containing cysteines in disulfide linkage(s) that are essential for biological activity; it is stable between pH 2 and pH 12 and after heating for 30 min at 560C but unstable at 1OOC.
Cellular growth and differentiation appear to be initiated, promoted, maintained, and regulated by a multiplicity of stimulatory, inhibitory, and synergistic factors and hormones. The alteration and/or breakdown of the cellular homeostasis mechanism is a fundamental cause of growthrelated diseases including neoplasia (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Physiological regulators of cell growth and differentiation, such as peptide growth factors (2, 4, 10, 11) , hematopoietic regulatory proteins (5, (12) (13) (14) , tumor necrosis factor types a and ,3 (8, 9) , interferons (15) , tumor inhibitory factor types 1 and 2 (16, 17) , oncostatin M (18) , leukoregulin (19) , and other less welldefined factors (20) (21) (22) can inhibit the proliferation of certain tumor cells, alter the tumor-cell phenotypes, and induce or modulate cell differentiation in vitro and in vivo. Furthermore, most of these regulatory factors elicit multiple biological effects that depend on the target cells and assay conditions (23) . Biologically active phorbol esters, such as phorbol 12-myristate 13-acetate (PMA) , are potent tumor-promoters in vivo, and they elicit and modulate a wide variety of biological and biochemical responses in vivo as well as in vitro (24) (25) (26) . It has been known for some time that PMA inhibits the growth of human breast adenocarcinoma cell line MCF-7 (27) . In addition, PMA also alters the morphology of MCF-7 cells and PMA-treated cells exhibit the morphological characteristics of secretory cells (27, 28) . We The supernatant was concentrated in an Amicon 2-liter concentrator with a YM10 membrane (Amicon) at 40C. When the volume of retenate became about 200 ml, 1 liter of cold Milli-Q-purified water was added and the mixture was reconcentrated to 200 ml.
The concentrate was removed and transferred to a precooled 250-ml Coming centrifuge bottle. Concentrated acetic acid was slowly added with stirring to a final concentration of 1 M acetic acid. The mixture was allowed to stand for 1 hr at 40C and centrifuged for 20 min at 40,000 x g at 40C. The supernatant was removed and dialyzed in Spectrapore dialysis tubing (number 3, molecular weight cutoff =3000) against 17 liters of 0.1 M acetic acid. The dialysis buffer was changed three times over a 2-day period. The retenate was Iyophilized. The dry material was removed, pooled, weighed, and stored at -20'C. We call this material crude powder.
Purification of AR. Crude powder (950 mg from =9 liters of serum-free conditioned medium) was suspended in 300 ml of 0.1% trifluoroacetic acid (F3CCOOH) and centrifuged for 20 min at 7000 x g. The supernatant was carefully removed and applied on a column ofpreparative C18 (2.54 cm x 27 cm; 55-105 gm; Waters Division of Millipore) equilibrated with 0.1% F3CCOOH in water. The flow rate was 4 ml/min and the chromatography was carried out at room temperature. The column was washed with 650 ml of0. 1% F3CCOOH in water. The flow through and wash were collected together. About 77% of total GIA activity appeared in the flow through and wash.
The flow-through and wash fraction were injected isocratically onto a preparative Partisil 10 (Fig. LA) . The early peak (eluting between 20%o and 23% MeCN) was further purified and characterized.
Fractions 47-62 were pooled and to that was added 224 ml of 0.1% F3CCOOH in water. The mixture was isocratically injected onto a semipreparative A-Bondapak-C18 column (7.8 x 300 mm, Waters Division ofMillipore). The linear gradient conditions were 0-17% acetonitrile in 10 min, 17-17% acetonitrile in 30 min, 17-25% acetonitrile in 320 min, and 25-100% acetonitrile in 40 min. The flow rate was 1 ml/min during the gradient and 4-ml fractions were collected. Two major peaks of activity were observed, eluting at acetonitrile concentrations of ==20% and =21%, respectively (Fig. IB) .
Fractions 49-53 were pooled and 20 ml of0. 1% F3CCOOH was then added to the pooled fraction. The mixture was applied onto an analytical ,t-Bondapak C18 column (3. trile in 20 min. The flow rate was 0.4 ml/min and 2-ml fractions were collected. Most of the activity emerged from the column at -21.5% acetonitrile concentration (Fig. 1C) . Fractions 54-59 (Fig. 1B) were pooled and chromatographed exactly as described above in Fig. 1C . Most of the activity was eluted from the column at an acetonitrile concentration of =22.2% (Fig. 1D) .
Fractions 35-38 (Fig. 1C) were individually concentrated to =70 ,ul to which was added an equal volume of acetonitrile containing 0.1% F3CCOOH. This 140-,ul sample was injected onto two Bio-Sil TSK-250 columns (7.5 x 300 mm each, BioRad) arranged in tandem. The elution was performed isocratically with a mobile phase of 50% (vol/vol) MeCN in H20 with 0.1% F3CCOOH at room temperature. The flow rate was 0.4 ml/min, 0.4-ml fractions were collected, and aliquots were assayed for GIA. Chromatographic profiles offractions 35, 36, and 37 ( Fig. 1C) are shown in Fig. 2 A-C (Fig. 1C). (B) HPLC ofconcentrated fraction 36 (Fig. 1C) . (C) HPLC of concentrated fraction 37 (Fig. 1C) . (D) HPLC of concentrated fractions 41 and 42 (Fig. 1D) .
of Edman degradation were performed prior to sample application. Identification of phenylthiohydantoin amino acid derivatives was carried out, on-line, on a model 120A phenylthiohydantoin analyzer (Applied Biosystems) by the method of Hunkapiller and Hood (32) .
RESULTS AND DISCUSSION
Production of AR by PMA-Treated MCF-7 Cells. MCF-7 cells grown on a plastic substratum exhibit epitheloid features: cells are small and polygonal in shape. PMA induces dramatic morphological changes in a dose-dependent manner. After PMA treatment, MCF-7 cells lose their welldefined morphology, become rounded, and spread out. PMA elicits a dose-dependent reduction in cell number and an increase in cell volume compared to untreated cells.
Serum-free conditioned medium from MCF-7 cells did not contain any detectable growth inhibitory activity for A431 cells. However, serum-free media collected from MCF-7 cells treated with PMA for 2-3 days were found to inhibit the proliferation of A431 epidermoid carcinoma cells. The optimum induction of inhibitory activity was observed at PMA concentrations between 25 and 100 ng/ml. Even after removing PMA, PMA-treated MCF-7 cells released this activity in serum-free medium for at least 8 days. Although a reduction in growth inhibitory activity was noticed with time after PMA removal, these results indicate that AR is either induced or increased in expression in MCF-7 cells that have been treated with PMA.
Initial Characterization of AR. The GIA was resistant to treatment with 1 M acetic acid, 1 M ammonium hydroxide, 6 M urea, 0.01 M sodium metaperiodate, to heating at 560C for 30 min, and to treatments with neuraminidase, N-Glycanase, O-Glycanase, lipase, or phospholipase A2, C, or D. However, activity was sensitive to heating at 100'C for 10 min, to reduction, to reduction and 4-vinylpyridine treatment, and to digestion with proteinases such as trypsin, endoproteinase Lys-C, endoproteinase Arg-N, and endoproteinase Glu-C (V-8). These results suggest that AR is a protein containing cysteines in disulfide linkage(s) that are essential for its biological activity. This protein may contain oligosaccharides and/or lipid moieties that are not obligatory for the biological activity.
Purification of AR and Certain Physical Properties. A summary of AR purification is presented in Table 1 . A 1842-fold purification with 5.1% yield has been achieved for Prep., preparatory; anal., analytical.
*One unit of GIA is the amount of factor required to inhibit '25I-labeled deoxyuridine incorporation into A431 cells by 50%.
tOther growth inhibitory activities are present in these fractions.
These values include all activities.
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